



Copy

1624 #4

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
<u>MARTIN A. HAY</u> Type or print name of person signing certification	
<u>[Signature]</u> Signature	<u>July 4, 2003</u> Date

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : LIEBESCHUETZ, John Walter  
MURRAY, Christopher William  
YOUNG, Stephen Clinton  
CAMP, Nicholas Paul  
JONES, Stuart Donald  
WYLIE, William Alexander  
MASTERS, John Joseph  
WILEY, Michael Robert  
SHEEHAN, Scott Martin  
ENGEL, David Birenbaum  
WATSON, Brian Morgan

RECEIVED  
JUL 08 2003  
TECH CENTER 1600/2900

Serial No. : 10/030,188 ✓  
Filed : 04 February 2002 ✓  
Group Art Unit: 1624  
Examiner : PATEL, Sudhaker B  
For : Serine Protease Inhibitors ✓  
Docket No. : 00217/US

By Facsimile (without Copies of References)

Confirmation (with Copies of References) by Courier

Serial No. 10/030,188

Commissioner for Patents  
US Patent & Trademark Office  
2011 South Clark Place  
Customer Window  
Crystal Plaza Two, Lobby, Room 1B03  
UNITED STATES

Sir:

**INFORMATION DISCLOSURE STATEMENT**

As a means of complying with the duty of disclosure, Applicant's submit an "Information Disclosure Statement by Applicant" on PTO Form PTO/SB/08A for consideration by the Examiner. Since this statement is being submitted during the period specified in 37 C.F.R. § 1.97(b), it is believed that no fee is due for this submission. However, should an Office Action on the merits have been mailed, please charge Deposit Account No. 50-1230 in the amount of the fee under 37 C.F.R. § 1.17(p), and consider the information under 37 C.F.R. § 1.97(c).

It is understood that the Examiner has received a copy of the International Search Report and copies of the documents cited therein (Documents B1, B2, B4, B5 and B21). If this is incorrect, the Examiner is kindly requested to contact the undersigned to request copies.

Document A2, which issued in April, 2003, claims priority from the same US provisional application as Document B18.

In addition, Applicants would like to provide the Examiner with the following background information:-

**BACKGROUND INFORMATION**

This application claims priority under 35 U.S.C. 119 from PCT/GB00/02302 (WO 00/76971, Document (B4)), which has entered the U.S. national stage as U.S. patent application serial number 09/926,712. The claims in the 09/926,712 application have been amended so as not to read on any of the compounds originally claimed in the present application.

The compounds claimed in this application were invented in the course of a research collaboration between Eli Lilly and Company (the assignee of record) and Protherics Molecular Design Limited (now Tularik Limited, a subsidiary of Tularik Inc). The predecessor company of Protherics Molecular Design Limited was Proteus Molecular Design Limited. By virtue of an agreement dated December 15, 1999, the invention claimed in the present application was subject to an obligation of assignment to Eli Lilly and Company at the time that the invention was made.

This application forms part of a portfolio of patent applications directed to serine protease inhibitors, some of which belong to Eli Lilly and Company, and some of which belong to Tularik Limited. The history of this portfolio traces back to a research project on serine protease inhibitors started by Proteus Molecular Design Limited. The undersigned is responsible for handling the applications in this portfolio.

A listing of the co-pending applications and patents in the portfolio is attached.

Eli Lilly and Company also owns a separate portfolio of applications and patents relating to serine protease inhibitors. PCT references belonging to this portfolio are


Serial No. 10/030,188

listed in the attached form PTO/SB/08A. Generally these PCT references have U.S. counterparts.

COMMUNICATION BY TELEPHONE

If the Examiner wishes to speak by telephone with the undersigned, the undersigned can be contacted by e-mail at martinahay@martin-a-hay.com, and would be pleased to telephone the Examiner in response.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Martin Alexander Hay', with a checkmark to its right.

Hay, Martin Alexander  
Agent for Applicants  
Registration No. 39,459  
Phone: 011 44 1625 500057  
e-mail: martinahay@martin-a-hay.com

Martin A. Hay & Co.,  
13 Queen Victoria Street  
Macclesfield  
Cheshire  
SK11 6LP  
UNITED KINGDOM

July 4, 2003

Serial No. 10/030,188

**Co-Pending Lilly and Tularik Applications and Patents**

**Co-pending applications - Assigned to Eli Lilly and Company**

09/926,712 (national stage of WO 00/76971 (B4))  
09/926,716 (national stage of WO 00/76970 (B5) - abandoned)  
10/030,187 (national stage of WO 01/96323)  
10/030,186 (national stage of WO 01/96304)  
10/030,189 (national stage of WO 01/96296)

**4. Co-pending applications and patents - Assigned to Tularik Limited**

US 6262069 and US 6420438 (national stage of WO 99/11657 (B1) and continuation)  
09/988,082 (continuation-in-part of 09/485,678, WO 99/11658 (B2) and of WO 00/77027 (B6))  
10/148,174 (national stage of WO 01/44226)  
10/296,245 (national stage of WO 01/96305)  
10/432,365 (national stage of WO 02/47762)